SK바이오팜, 세노바메이트 질주에 역대 최대 실적…‘빅 바이오텍’ 선순환 본격화
SK Biopharm achieved record-high performance driven by Cenobamate (Xcopri), with significant increases in sales and operating profit, and plans to expand into new drug areas.
How this call is verified
The ▲ Bullish call is auto-verified against the actual S&P 500 price shortly.
Bar: S&P 500 ±0.3% within 24h · every verdict lands on the public ledger
Key takeaway
"SK바이오팜, 세노바메이트 질주에 역대 최대 실적…‘빅 바이오텍’ 선순환 본격화" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 75 out of 100. SK Biopharm achieved record-high performance driven by Cenobamate (Xcopri), with significant increases in sales and operating profit, and plans to expand into new drug areas. Reported by Maeil Business on May 07, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.